Alector, Inc. Stock News

Alector, Inc. - Special Call Company Participants Katie Hogan - Senior Director of Corporate Communication & Investor Relations Sara Kenkare-Mitra - President and Head of Research & Development Arnon Rosenthal - Co-Founder, CEO & Director Giacomo Salvadore - Chief Medical Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Myles Minter - William B...

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced management will host a virtual event to discuss the company's progranulin (PGRN) franchise and Alector Brain Carrier (ABC)–enabled programs.

Alector, Inc. (NASDAQ:ALEC ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:00 AM EDT Company Participants Arnon Rosenthal - Co-Founder, CEO & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley Global Healthc...

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2025 (New York, New York) Thurs...

Alector, Inc. (NASDAQ:ALEC ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Arnon Rosenthal - Co-Founder, CEO & Director Giacomo Salvadore - Chief Medical Officer Katie Hogan - Senior Director of Corporate Communication & Investor Relations Neil Berkley - Interim CFO & Chief Business Officer Saraswati Kenkare-Mitra - President and Head of Research & Development ...

Alector (ALEC) Q2 Revenue Falls 48%

On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease expected to complete in 2026 Continuing to progress Alector Brain Carrier programs, including the company's anti-amyloid beta antibody, engin...

Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT